Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

6 years ago
People
Pharma

Unum racks up yet an­oth­er FDA hold as it twists its way through a re­struc­tur­ing, look­ing for a fresh start with a ...

6 years ago
R&D

In­ovio files for $50M of­fer­ing amid Covid-19 vac­cine hunt; Zy­dus Cadi­la signs on with XO­MA on IL-2 deal

6 years ago
News Briefing

Chi­nese biotech bags $50M+ for I/O, au­toim­mune work, start­ing with ALK5 in­hibitor

6 years ago
Financing
China

Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

6 years ago
R&D
Cell/Gene Tx

ACC scraps its flag­ship event in Chica­go as Covid-19 fears spread faster than the virus

6 years ago
Coronavirus

With pos­i­tive key tri­al, Kala Phar­ma's dry eye drug Ey­su­vis em­u­lates ap­proval path set by Xi­idra

6 years ago
R&D

Bio­phar­ma stocks take a beat­ing as eco­nom­ic tur­moil takes its toll — but some play­ers with coro­n­avirus ef­forts ...

6 years ago
Coronavirus

Neil Wood­ford in the game to buy back his for­mer un­list­ed port­fo­lio that's prov­ing hard to sell — re­ports

6 years ago
Financing
Deals

FDA ap­proves ex-No­var­tis drug for Cush­ing’s dis­ease

6 years ago
Pharma

Tri­fec­ta of clin­i­cal stage biotechs un­veil IPO plans, brav­ing Wall Street's coro­n­avirus pan­ic

6 years ago
Financing

Mit­subishi joins Ei­sai, 3SBio's bet on mul­ti­spe­cif­ic an­ti­bod­ies, up­ping Num­ab's Se­ries B haul to $23M+

6 years ago
Financing

As Bio­gen grap­ples with coro­n­avirus cri­sis, Big Phar­mas like Eli Lil­ly, Take­da hun­ker down, tell staffers to work ...

6 years ago
Pharma
Coronavirus

Tal­ly of coro­n­avirus cas­es at Bio­gen spikes by 15 on Sun­day — and Cowen says one in­fect­ed ex­ec at­tend­ed big ...

6 years ago
Coronavirus

Bio­gen man­dates quar­an­tine, new work-from-home mea­sures for most staffers as coro­n­avirus trig­gers 5 more in­fec­tions

6 years ago
Coronavirus

Coro­n­avirus up­date: Trump signs $8.3B spend­ing bill in­to law; Pfiz­er con­sid­ers mR­NA vac­cine pact with BioN­Tech

6 years ago
News Briefing

Eu­ro­pean reg­u­la­tors ex­pand use of Ab­b­Vie's two-month hep C reg­i­men

6 years ago
Pharma

Tiny Treve­na re­turns to FDA in sec­ond bid for con­tro­ver­sial opi­oid painkiller

6 years ago
FDA+

Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's ...

6 years ago
Deals

Abrax­ane de­vel­op­er Igle­sias joins Sen­ti Bio­sciences; AB2Bio re­cruits CEO

6 years ago
Peer Review

Se­ri­ous side ef­fects side­line small Roche study of an ex­per­i­men­tal Hunt­ing­ton’s drug from Io­n­is

6 years ago
R&D

Lob­by­ing cam­paign killed pro­pos­al to set price lim­its on fu­ture coro­n­avirus drugs, vac­cines — re­port

6 years ago
R&D
Coronavirus

Dana-Far­ber, MD An­der­son, MIT im­pose trav­el re­stric­tions amid broad­er ef­forts to con­tain coro­n­avirus dam­age in US

6 years ago
Coronavirus

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ...

6 years ago
R&D
Pharma
First page Previous page 855856857858859860861 Next page Last page
A service from the Financial Times